USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A REVIEW OF CLINICAL AND INTERVENTION STUDIES
Abstract
Introduction: Inflammatory bowel disease (IBD) is a general term used to describe a group of chronic inflammatory diseases of the gastrointestinal tract with complex etiologies. They mainly include Crohn's disease (CD) and ulcerative colitis (UC) .
Purpose of the work: The purpose of this paper is to present current knowledge on the use of cannabinoids in the treatment of inflammatory bowel disease, with a particular focus on their impact on patient well being.
Material and methods: The study is based on a review of the scientific literature, including clinical and experimental studies on the effects of cannabinoids on the gastrointestinal tract and their use in the treatment of IBD.
Results: The endocannabinoid system (ECS) plays an important role in modulating many physiological processes, including maintenance of intestinal homeostasis, regulation of intestinal function, visceral sensation, modulation of gastrointestinal motility and immunomodulation of inflammation in IBD. Studies have shown that their use leads to a reduction in abdominal pain, emotional distress, stool frequency and anorexia nervosa. They also found higher rates of depression, smoking and alcohol consumption among IBD patients who used cannabis. The long-term safety profile of cannabinoids in IBD patients has not been established.
Summary: Cannabinoids have the potential to be effective supportive therapies for inflammatory bowel disease, but more research is needed to determine their long-term safety and optimal dosage.
References
Hryhorowicz S., Kaczmarek-Ryś M., Zielińska A., Scotta R., Słomski R., Pławski A. (2021) The endocannabinoid system as a promising therapeutic target in inflammatory bowel disease-a systematic review. Frontal Immunol, 12:790803. https://doi.org/10.3389/fimmu.2021.790803
Sen A. (2022) Complementary drugs for ulcerative colitis and unintended interactions with cytochrome P450-dependent drug metabolizing enzymes. Turk J Med S.C., 52(5), 1425-1447. https://doi.org/10.55730/1300-0144.5482
Meletis K. (2019) The important role of the endocannabinoid system and endocannabinoidome in gut health. Altern Ther Health Med., 25(S2), 24-28. https://pubmed.ncbi.nlm.nih.gov/31202201
Wolyniak M., Malecka-Wojciesko E., Zielińska M., Fabisiak A. (2022) Interaction between cannabinoid receptors and nociceptin receptors in colitis - clinical implications. J Clin Med., 11(22), 6675. https://doi.org/10.3390/jcm11226675
Cuddihey H., MacNaughton W., Sharkey K. (2022) The role of the endocannabinoid system in regulating intestinal homeostasis. Cell Mol Gastroenterol Hepatol, 14(4), 947-963. https://doi.org/10.1016/j.jcmgh.2022.05.015
Lee Y., Jo J., Young Chung H. (2016) Endocannabinoids in the gastrointestinal tract. https://doi.org/10.1152/ajpgi.00294.2015
Priscila A., Berg B., Castor M. (2022) Involvement of the cannabinoid system in chronic inflammatory bowel disease: potential for new therapies. Intest Res, 20(4):392-417. https://doi.org/10.5217/ir.2021.00160
Duczmal D., Bazan-Wozniak A., Niedzielska K., Pietrzak R. (2024) Cannabinoids - multifunctional compounds, applications and challenges - a mini review. Molecules, 29(20):4923. https://doi.org/10.3390/molecules29204923
Picardo S., Kaplan G., Sharkey K., Seow H. (2019) Insights into the role of cannabis in the treatment of inflammatory bowel disease. Therap Adv Gastroenterol. Rzesień 3;12:1756284819870977. https://doi.org/10.1177/1756284819870977
Crowley K., Luke Kiraga Ł., Miszczuk E., Skiba S., Banach J., Latek U., Mendel M., Chłopecka M. (2024) Effects of cannabinoids on intestinal peristalsis, barrier permeability and therapeutic potential in gastrointestinal diseases. Int J Mol Sci, 25(12):6682. https://doi.org/10.3390/ijms25126682
Swaminath A., Berlin E., Cheifetza A., Hoffenberg E., Kinnucan J., Wintage L., Buchanan S., Zmeter N., Rubin D. (2018) The role of cannabis in the treatment of inflammatory bowel disease: a review of clinical, scientific and regulatory information. Inflammatory bowel disease, 25(3). 427–435. https://doi.org/10.1093/ibd/izy319
Buckley M., Kumara A., Swaminath A. (2021) Inflammatory bowel disease and cannabis: a practical approach for clinicians. Adv Ther, 38(7), 4152-4161. https://doi.org/10.1007/s12325-021-01805-8
Legare Ch., Raup-Konsavage W., Vrana K. (2022) Therapeutic potential of cannabis, cannabidiol and cannabinoid-based pharmaceuticals. Pharmacology, 107(3-4), 131-149. https://doi.org/10.1159/000521683
Brodaric A., Polikarpova A., Hong J. (2024) Cannabinoids in inflammatory bowel disease: a scoping review. Research on cannabis and cannabinoids. https://doi.org/10.1089/can.2024.0061
Alves de Carvalho A., Achete de Souza G., Vaz de Marqui S., Langraf Guiguer E., Cressoni Araújo A., José Rubira C., Buchaim R., Barbalho S. (2020) Cannabis and cannabinoids for inflammatory bowel disease: moving beyond misuse. Int J Mol Sci, 21(8), 2940. https://doi.org/10.3390/ijms21082940
Kang H., Schmoyer Ch., Weiss A., Lewis J. (2025) Meta-analysis of the therapeutic effects of cannabinoids in inflammatory bowel disease. Inflammatory bowel diseases. 31(2), 450-460. https://doi.org/10.1093/ibd/izae158
Kafil T., Nguyen T., MacDonalda J., Chande N. (2018) Cannabis in the treatment of Crohn's disease. Cochrane Syst Rev database, Article 11(11):CD012853. https://doi.org/10.1002/14651858.cd012853.pub2
Quezada S., Cross R. (2019) Cannabis and turmeric as complementary treatments for IBD and other gastrointestinal diseases. Curr Gastroenterol Rep, 21(2):2. https://doi.org/10.1007/s11894-019-0670-0
Bilbao A., Spanagel R. (2022) Medical cannabinoids: a systematic review and pharmacology-based meta-analysis for all relevant medical indications. BMC Med., 20, 259. https://doi.org/10.1186/s12916-022-02459-1
Hoch E., Wolkow N., Friemel C., Lorenzetti V., Freeman T., Hall W. (2025) Cannabis, cannabinoids and health: a review of the evidence on medical risks and benefits. Eur Arch Psychiatry Clin Neurosci, 275(2), 281-292. https://doi.org/10.1007/s00406-024-01880-2
Coatesa M., Dalessio S., Walter V., Stuart A., Bernasko N., Tinsley A., Razeghi S., Williams E., Clarke K., Vrana K. (2022) Extraintestinal symptoms and signs in active cannabis users with inflammatory bowel disease. Cannabinoid from Cannabis Res, 7(4), 445-450. https://doi.org/10.1089/can.2020.0155
Views:
35
Downloads:
20
Copyright (c) 2025 Anita Janda, Magdalena Rosiewicz, Marcin Durowicz, Iwona Górnicka, Aleksandra Pastuszek, Karolina Bieńkowska, Jan Drzymała, Urszula Kierepka, Sylwia Bartolik
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
